Related Experiment Video
Updated: Aug 14, 2026

Multispectral Real-time Fluorescence Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology
Published on: October 20, 2010
Indocyanine green delivery systems for tumour detection and treatments
Elena P Porcu1, Andrea Salis2, Elisabetta Gavini2
1PhD in Experimental Medicine, Department of Diagnostic, Paediatric, Clinical and Surgical Science, Pavia, Italy.
Abstract:
Indocyanine green (ICG) is a cyanine compound that displays fluorescent properties in the near infrared region. This dye is employed for numerous indications but nowadays its major application field regards tumour diagnosis and treatments. Optical imaging by near infrared fluorescence provides news opportunities for oncologic surgery. The imaging of ICG can be useful for intraoperative identification of several solid tumours and metastases, and sentinel lymph node detection. In addition, ICG can be used as an agent for the destruction of malignant tissue, by virtue of the production of reactive oxygen species and/or induction of a hyperthermia effect under irradiation. Nevertheless, ICG shows several drawbacks, which limit its clinical application. Several formulative strategies have been studied to overcome these problems. The rationale of the development of ICG containing drug delivery systems is to enhance the in vivo stability and biodistribution profile of this dye, allowing tumour accumulation and resulting in better efficacy. In this review, ICG containing nano-sized carriers are classified based on their chemical composition and structure. In addition to nanosystems, different formulations including hydrogel, microsystems and others loaded with ICG will be illustrated. In particular, this report describes the preparation, in vitro characterization and in vivo application of ICG platforms for cancer imaging and treatment. The promising results of all systems confirm their clinical utility but further studies are required prior to evaluating the formulations in human trials.
Insights
Indocyanine green (ICG) dye shows promise for cancer imaging and treatment. Formulations using ICG in nanocarriers enhance its stability and tumor accumulation, improving efficacy for oncologic applications.
Area of Science:
- Biomedical Engineering
- Optical Imaging
- Nanotechnology
Background:
- Indocyanine green (ICG) is a near-infrared fluorescent dye with applications in tumor diagnosis and treatment.
- ICG facilitates intraoperative identification of tumors, metastases, and sentinel lymph nodes.
- ICG can induce malignant tissue destruction via reactive oxygen species or hyperthermia.
Purpose of the Study:
- To review ICG-containing drug delivery systems for enhanced cancer imaging and treatment.
- To classify ICG nanocarriers based on composition and structure.
- To illustrate various ICG formulations, including nanosystems, hydrogels, and microsystems.
Main Methods:
- Classification of ICG-loaded nanocarriers by chemical composition and structure.
- Description of preparation and in vitro characterization of ICG platforms.
- Review of in vivo applications of ICG formulations for cancer therapy.
Main Results:
- ICG-containing nanocarriers demonstrate improved in vivo stability and biodistribution.
- These systems enable targeted tumor accumulation, leading to enhanced efficacy.
- Various ICG formulations show promising results for cancer imaging and treatment.
Conclusions:
- ICG-based drug delivery systems offer significant potential for clinical oncology.
- Nanosystems, hydrogels, and microsystems loaded with ICG improve dye performance.
- Further human trials are necessary to fully evaluate the clinical utility of these formulations.
More Related Videos
04:01Indocyanine Green-Guided Intraoperative Imaging to Facilitate Video-Assisted Retroperitoneal Debridement for Treating Acute Necrotizing Pancreatitis
Published on: September 8, 2022
14:56Application of Indocyanine Green Fluorescence Imaging Technology in Laparoscopic Duodenum-Preserving Pancreatic Head Resection
Published on: November 21, 2025